The Cancer Immunotherapy Consortium (CIC), a program of the US-based nonprofit Cancer Research Institute, is an international association of pharmaceutical and biotechnology companies and academic institutions that share a common interest in immunotherapy research and development. 

CIC’s mission is to improve patient care by making cancer immunotherapies part of the standard-of-care in oncology.  CIC provides a platform that allows its stakeholders to advance the field by working together to achieve solutions to scientific and developmental challenges creating a single and powerful voice within the biomedical research community.

Founded in 2002 as the Cancer Vaccine Consortium (CVC), CIC amended its name in early 2010 to represent more accurately the broader diversity of the many promising clinical developments in immune-based treatment of cancer beside vaccines, including monoclonal antibodies and other modulators of immunity. 

The new name emphasizes to our membership and the greater community that CIC has and will continue to provide coverage of all types of cancer immunotherapy.  CIC continues to offer our membership the best academic and industry expertise in the immunotherapy field.